AU2021244313A1 - Method for treating diabetes - Google Patents

Method for treating diabetes Download PDF

Info

Publication number
AU2021244313A1
AU2021244313A1 AU2021244313A AU2021244313A AU2021244313A1 AU 2021244313 A1 AU2021244313 A1 AU 2021244313A1 AU 2021244313 A AU2021244313 A AU 2021244313A AU 2021244313 A AU2021244313 A AU 2021244313A AU 2021244313 A1 AU2021244313 A1 AU 2021244313A1
Authority
AU
Australia
Prior art keywords
day
dapansutrile
subject
diabetes
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021244313A
Other languages
English (en)
Inventor
Charles A. Dinarello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Olatec Therapeutics Inc
Original Assignee
Olatec Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olatec Therapeutics Inc filed Critical Olatec Therapeutics Inc
Publication of AU2021244313A1 publication Critical patent/AU2021244313A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
AU2021244313A 2020-03-25 2021-03-22 Method for treating diabetes Pending AU2021244313A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062994486P 2020-03-25 2020-03-25
US62/994,486 2020-03-25
PCT/US2021/023497 WO2021194975A1 (en) 2020-03-25 2021-03-22 Method for treating diabetes

Publications (1)

Publication Number Publication Date
AU2021244313A1 true AU2021244313A1 (en) 2022-11-17

Family

ID=77890597

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021244313A Pending AU2021244313A1 (en) 2020-03-25 2021-03-22 Method for treating diabetes

Country Status (7)

Country Link
US (1) US12569463B2 (https=)
EP (1) EP4132505A4 (https=)
JP (1) JP2023518829A (https=)
CN (1) CN115279363A (https=)
AU (1) AU2021244313A1 (https=)
MX (1) MX2022011651A (https=)
WO (1) WO2021194975A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115089572A (zh) * 2022-07-18 2022-09-23 南通大学 一种化合物olt1177在制备治疗2型糖尿病药物制剂中的应用
CN119632971A (zh) * 2024-09-10 2025-03-18 浙江大学 一种达泮舒腈的应用及药物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2970485T3 (es) * 2017-01-06 2024-05-29 Olatec Therapeutics Llc Composición farmacéutica para su uso en el tratamiento de enfermedades cardiovasculares
WO2018204764A1 (en) * 2017-05-05 2018-11-08 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
CN111094242B (zh) * 2017-07-24 2024-02-09 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物

Also Published As

Publication number Publication date
US12569463B2 (en) 2026-03-10
MX2022011651A (es) 2022-10-13
EP4132505A4 (en) 2024-04-24
CN115279363A (zh) 2022-11-01
EP4132505A1 (en) 2023-02-15
JP2023518829A (ja) 2023-05-08
US20230028615A1 (en) 2023-01-26
WO2021194975A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
Scheen Clinical pharmacokinetics of metformin
Anderson et al. Dapagliflozin for the treatment of type 2 diabetes
Fatima et al. Metformin and its gastrointestinal problems: A review
US12569463B2 (en) Method for treating diabetes
US12318361B2 (en) Methods for treating cardiovascular diseases
US20250000933A1 (en) Terlipressin compositions and their methods of use
EP3856478A1 (en) Formulations for treatment of dry eye disease
JP2020504128A (ja) Ｇｌｐ−１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
Sosale et al. A prospective analysis of the efficacy and safety of sodium glucose cotransporter 2 inhibitors: real world evidence from clinical practice in India
US20200170990A1 (en) Method for treating schnitzler's syndrome
US20240358669A1 (en) Methods for treating pancreatic cancer
CN103356640A (zh) 糖皮质激素应用于制备治疗和改善Graves眼病药物
WO2025124465A1 (en) Method for treating atopic dermatitis
CN113226374B (zh) 含氨氯地平、氯噻酮和醛固酮受体拮抗剂的药物组合物
US20250177488A1 (en) Compositions and methods for treating diabetes
Khan et al. Drug-drug interaction between ciprofloxacin and diclofenac ophthalmic drops at ocular level
Hemalatha et al. A COMPARATIVE STUDY ON EFFICACY AND SAFETY OF TENELIGLIPTIN AND CANAGLIFLOZIN IN TYPE 2 DIABETES PATIENTS
Dalvi et al. Ertugliflozin: A Novel Drug for Control of Type-2 Diabetes
Islam et al. Efficacy and Safety of SGL-2 Inhibitor Dapaglifozine as Add on Therapy in Patient of Type-2 Diabetes Mellitus
CN105213398B (zh) 一种治疗糖尿病的药物组合物
JPH10114682A (ja) グルコマンナン配合持効性内服用薬剤
HK40073572B (zh) 酒精性肝炎的治疗
WO2020207355A1 (zh) 含氨氯地平、氯噻酮和阿米洛利的药物组合物
Dalvi et al. Ertugliflozin: A Novel Drug f or Control o f Type-2 Diabetes
CN110062634A (zh) 非酒精性脂肪肝病患者中纤维化的抑制